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days of the “hot preps” were usually Thursdays and
would involve Ce´sar and John Jarvis, his research asso-
ciate, garbed in full-length lead aprons, spinning 5 liters
Ce´sar Milstein: October 8, 1927–
March 24, 2002
or more of radioactive myeloma cells to concentrate
them into a few milliliters. This would invariably result
in a trail of radioactivity across the corridor from the
cold room to the hot room where these procedures wereCe´sar Milstein died in the early hours of 24th March 2002.
carried out. These studies, plus immunoglobulin proteinHe had a long history of cardiovascular illness, to which
synthesis work, showed that the precursor of the lighthe finally succumbed. We will always remember his en-
chain was made with a hydrophobic leader sequencethusiasm for science and his kind attention to the prob-
for specifying transfer to the endoplasmic reticulum.lems of others. His most famous contribution to biology
Ce´sar always tackled scientific problems from manywas the invention of monoclonal antibodies (also called
angles, and he was not content with straight molecularhybridomas, but that was a term he never really liked)
biology. Rather, he was also keen to see if cells couldfor which he was awarded the Nobel Prize for Physiology
discriminate immunoglobulin heavy and light chains ofor Medicine in 1984, along with George Kohler, who
differing origins, and he set about fusing rat and mouseworked with Ce´sar on the key experiments that led to
immunoglobulin-producing cell lines. With Dick Cotton,their landmark paper, published in Nature in 1975.
many experiments were done to show how heavy andCe´sar was born in Argentina in 1927 and developed
light chains associate. Later, George Kohler joined Ce´-an early interest in immunology through family connec-
sar’s group as a post-doc. Together they hatched thetions; this was an enthusiasm that was to last throughout
idea of fusing spleen cells with mouse myeloma tissuehis sparkling career. After being a none-too-keen
culture cells to immortalize the spleen immunoglobulinschoolboy, he went to Buenos Aires University to study
and, of course, the stroke of brilliance here was thatchemistry. He obtained a BSc and then a Ph.D. studying
preimmunizing mice with antigen allowed predefinedaldehyde dehydrogenase in the laboratory of Andres
Stoppani. He later traveled to Cambridge, England, and
worked in the University Department of Biochemistry
with Malcolm Dixon, where he obtained a second Ph.D.
with studies on the phosphoglucomutase enzyme. It
was in the Department of Biochemistry that Ce´sar met
Fred Sanger, who was to be influential in attracting him
back to Cambridge after a brief sojourn in his old Buenos
Aires Institute as Head of Molecular Biology. Ce´sar’s
move to the then-fledgling Laboratory of Molecular Biol-
ogy with Fred, and a truly extraordinary group of scien-
tists (Brenner, Crick, Huxley, Kendrew, Klug, Perutz),
was a wonderful opportunity for him as the MRC support
allowed his research to blossom by setting few con-
straints on what he could do. How well-suited this envi-
ronment must have been for the young Milstein! The
intellectual environment was second to none, and it was
there that he developed an interest in antibody structure
and diversity, unfettered by the needs of the next grant
proposal or the next peer review committee.
An interest in antibody diversity was to stretch from
those early times until Ce´sar’s death (he had submitted
a paper to PNAS just the week before he died). When
he joined the Laboratory of Molecular Biology, he started
thinking about potential roles of germline immunoglobu-
lin gene diversity or of somatic diversification of those
genes, and he came to the conclusion that the latter
mechanism must lie at the heart of antibody diversity.
This one fundamental belief was the precursor for the
work that was eventually to lead to his Nobel Prize-
winning work with Kohler. In his attempts to solve the
issue of somatic diversification, Milstein collaborated
with George Brownlee on pioneering sequencing work
of immunoglobulin light-chain mRNA. This involved la-
beling mouse myeloma cells with50 mCi 32P, followed
by preparation of purified mRNA for fingerprinting. The Ce´sar Milstein
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antibody specificities to be captured. This became rants that were able to cope with his strict dietary re-
monoclonal antibody technology. Their paper was pub- gime, and of course high tables in the Cambridge
lished in 1975, and the Nobel Prize was awarded in 1984. colleges were not spared. Occasionally, Ce´sar gave in
Ce´sar was awarded innumerable additional prizes for to impulse, such as his nearly disastrous white-water
this work. He received other accolades such as the Com- rafting in Chile, during which he had a “life-threatening
panion of Honor in 1995, and he became the first recipi- cardiovascular episode,” as he casually put it when he
ent of the MRC Millennium Medal in 2000. He was a returned to work. However, he was generally tenacious
Fellow of the Royal Society of London and of the Na- in his health regime; one often reads of people fighting
tional Academy of Sciences. their disease, but Ce´sar truly did.
Monoclonal antibody technology was revolutionary Ce´sar’s qualities as a researcher go without saying,
because, for the first time, pure antibody species of but I am sure he would not mind my saying that he was
defined specificity could be made. This had far-reaching not a well-organized scientist. He would not come to
implications for biological research and for clinical use the lab with a list of “things to do today.” Rather, his style
(diagnostics and, more recently, therapeutics). Early in was intellectual, grasping at problems as they arose in
the development of monoclonal antibodies, Ce´sar the laboratory simply for their sake as scientific prob-
started to work on monoclonals recognizing surface an- lems. He always seemed to have masses of time to
tigen markers and blood groups. Monoclonal antibodies discuss and mull over data. His suggestions were not
are now the basis of many diagnostic assays for proteins always the most down-to-earth, but therein lay his bril-
in clinical laboratories and have important uses in such liance; at one time completely outlandish and at another
areas as cancer imaging. Now their value as therapeutic focused and hitting the spot. Those of us who had the
agents is at last beginning to emerge. For instance, privilege to work at the Laboratory of Molecular Biology
we have recently heard about Herceptin, a monoclonal with Ce´sar over the years will remember him as a father
antibody that binds to a surface receptor and is proving figure and a friend. He used to describe the Laboratory
important in management of breast cancers. Therapeu- of Molecular Biology as the “beloved Laboratory,” and
tic use of monoclonal antibodies had been Ce´sar’s that was his inspiration. There was another side to
dream, and he had the gratification of seeing the process Ce´sar, and it was the one who loved his wife Celia, whom
put into practice. Discussions about whether mono- he married in 1953, who loved his home, his garden, his
clonal antibodies should have been patented in 1975 boat, and manifold other special things in life like music,
have occupied many people. However, we should re- art, cinema, and theater. Of all the things we shall re-
member the immense importance of the invention, member about Ce´sar, his enthusiasm for science was
which was nurtured from essentially curiosity-driven re- special. At Ce´sar’s funeral, Michael Neuberger told us
search. As with almost all inventions, hybridoma tech- that Ce´sar had mentioned in a recent press interview
nology seems blindingly obvious many years later, but that he wished to be remembered as a nice chap. As
the fact remains that monoclonal antibodies are just Michael said, Ce´sar’s wish has been granted many times
beginning to be widely accepted for treatment regimes over, “he was a very nice chap.”
(and at this time, of course, an original monoclonal anti-
body patent would be off-patent!). Terence H. Rabbitts
After hybridomas, Ce´sar remained true to his early MRC Laboratory of Molecular Biology
scientific obsession (namely, how somatic mutation Hills Road
Cambridge CB2 2QHarises in immunoglobulin genes) despite his success
United Kingdomwith monoclonal antibodies and the acclaim this brought
him. He mapped out patterns of changes observed dur-
ing antibody responses using primer-directed cDNA se-
quencing. This work charted the course of somatic di-
versification in an immune response. Even when Ce´sar
formally retired in 1995, he remained an active member
of the Protein and Nucleic Acid Chemistry Division in the
Laboratory of Molecular Biology. In his postretirement
years, he continued his interest in the origin of somatic
mutation and, in collaboration with Michael Neuberger,
he had begun to dissect the enzymatics of the process.
Indeed, Ce´sar’s only concession to retirement was not
to work on Saturdays any more. Ce´sar was a prolific
writer and published 313 papers in his lifetime, each
composed with his characteristic precision.
The way that Ce´sar confronted the symptoms of his
cardiovascular illness was typical of him. His illness was
first diagnosed some 20 years ago, and he set about
finding all the data he could about it, examining it and
deciding how he was going to fight it. He switched from
a high-cholesterol diet to low-cholesterol salads and
the like, and he immediately took to long walks around
Cambridge, before and after work, to stimulate his circu-
lation. He identified a series of local and London restau-
